InspireMD Ltd. is announcing the availability of a new and improved delivery system, for its MGuard™, coronary stent system. The new delivery system which has already been introduced in selected regions around the world will now make its launch in South America.
The new delivery system offers a state of the art design and superior deliverability. "We are very pleased with the flexibility and performance of the new delivery system. In our testing we have experienced a 15% improvement in crossing profile and 45% improvement in pushability resistance. These improvements will directly benefit coronary patients in Latin America and throughout the world," said Eli Bar, CTO and VP R&D of InspireMD.
Some of the unique advantages of the MGuard stent were presented during the SOLACI congress:
· Dr. Gian Battista Danzi discussed the “New Methods to Treat Distal Embolization with the Micro-Mesh Covered Stent” at 10:30 on Wednesday, August 11th at the Pacara Hall of the Hilton Hotel.
· Dr. Cleverson Zukowski presented a case of “Residual Intra-stent thrombosis after Coronary Angioplasty in a Critical Artery of a Patient with Acute Coronary Syndrome” at 10:30 on Thursday, August 12th at the Sauce Hall of the Hilton Hotel.
Furthermore, results from the MAGICAL study and the iMOS registry were displayed as posters
· “Six-month results of mesh covered stent implantation in ST-segment elevation myocardial infarction”
· “Real-world data of the MGuard coronary stent: Early data from the iMOS Registry”
About MGuard™ Coronary
MGuard™ presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard™ coronary stent provides permanent embolic protection, without complicating deliverability. MGuard™ is CE Mark approved. The MGuard™ Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.
About InspireMD
InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.
